LON:IXI IXICO (IXI) Share Price, News & Analysis GBX 12.50 +0.50 (+4.17%) As of 08/7/2025 10:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About IXICO Stock (LON:IXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IXICO alerts:Sign Up Key Stats Today's Range 11.56▼ 12.5050-Day Range 9.50▼ 13.1652-Week Range 6.96▼ 15Volume14,301 shsAverage Volume52,239 shsMarket Capitalization£11.58 millionP/E RatioN/ADividend Yield1.27%Price TargetN/AConsensus RatingN/A Company Overview IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials. The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the Platform and IXICO’s expert scientists translating complex data into clinically meaningful while minimising data variability and increasing reproducibility. The approach enables research scientists to make better informed decisions earlier in the drug development process. The Company is an expert iCRO and technology partner in neuroimaging, pioneering new capabilities in neurodegeneration biomarker research such as vascular pathology in AD and the measurement of Neuromelanin accumulation in PD and inflammatory processes across neurodegenerative diseases. IXICO’s mission is advance medicine and patient outcomes through the sophisticated measurement and analysis of existing and previously inaccessible disease signalling biology. The latest generation of the Platform positions IXICO’s technology beyond its traditional iCRO remit and opens opportunities to expand into diagnostics, mechanistic disease understanding, patient selection/stratification, pre-clinical drug candidate validation, post-marketing surveillance and clinical decision support. IXICO’s technology is being used every day across the world. Clients and partners use IXICO for its advanced technology, scientific expertise and service excellence. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world. The Company is dedicated to delivering better outcomes for patients and is a key part of the global neurological disease research community with a proven track record in the biopharmaceutical industry working with leading pharma companies, innovative biotech’s, disease consortia and non-profit organisations. As the prevalence and understanding of neurological conditions increases there is an urgent need to find better treatments. Neurological conditions are now the leading cause of disability worldwide and the second leading cause of death after cardiovascular disease. Approximately 3.4 billion people, equivalent to 43% of the global population, were affected by conditions impacting the nervous system. AD is believed to affect more than 55 million people globally, a figure projected to reach 78 million by 2030. PD is the second most prevalent neurodegenerative condition after AD with global, estimates projecting that more than 10 million people are living with the disease. Read More Receive IXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IXICO and its competitors with MarketBeat's FREE daily newsletter. Email Address IXI Stock News HeadlinesGlobal Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 StudyJuly 22, 2025 | finance.yahoo.comIxico expects return to profitability as annual revenue set to riseJuly 17, 2025 | lse.co.ukAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)IXICO plc Expects Revenue Growth to Surpass Expectations in 2025July 17, 2025 | tipranks.comMavs Shutting Down Cooper Flagg after Stellar 31-Point Game Angers Fans: “Load Management in Summer League”July 13, 2025 | msn.comIXICO plc Issues Share Options and Announces Director Share DealingsJune 13, 2025 | tipranks.comIxico cheers FDA approval for contractor Fujirebio's Alzheimer's testJune 10, 2025 | lse.co.ukIXICO plc Announces Shareholder Name Change NotificationMay 20, 2025 | tipranks.comSee More Headlines IXI Stock Analysis - Frequently Asked Questions How have IXI shares performed this year? IXICO's stock was trading at GBX 12.50 at the beginning of the year. Since then, IXI stock has increased by 0.0% and is now trading at GBX 12.50. How were IXICO's earnings last quarter? IXICO plc (LON:IXI) announced its quarterly earnings results on Tuesday, May, 20th. The company reported ($1.11) earnings per share (EPS) for the quarter. IXICO had a negative trailing twelve-month return on equity of 19.14% and a negative net margin of 31.10%. How do I buy shares of IXICO? Shares of IXI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of IXICO own? Based on aggregate information from My MarketBeat watchlists, some other companies that IXICO investors own include BioNTech (BNTX), Benefitfocus (BNFT), Grayscale Bitcoin Trust ETF (GBTC), Motif Bio (MTFB), Pfizer (PFE), Tesla (TSLA) and VEON (VEON). Company Calendar Last Earnings5/20/2025Today8/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IXI CIKN/A Webixico.com Phone+44-20-37637499FaxN/AEmployees89Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (3.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-0.38Net Income-£3.58 million Net Margins-31.10% Pretax MarginN/A Return on Equity-19.14% Return on Assets-10.40% Debt Debt-to-Equity Ratio3.32 Current Ratio2.85 Quick Ratio4.90 Sales & Book Value Annual Sales£11.50 million Price / Sales1.01 Cash FlowGBX 5.56 per share Price / Cash Flow2.25 Book ValueGBX 19.57 per share Price / Book0.64Miscellaneous Outstanding Shares92,668,597Free FloatN/AMarket Cap£11.58 million OptionableNot Optionable Beta0.86 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:IXI) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IXICO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share IXICO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.